Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Forum for Health Economics & Policy

Editor-in-Chief: Goldman, Dana

2 Issues per year


CiteScore 2016: 0.30

SCImago Journal Rank (SJR) 2016: 0.140
Source Normalized Impact per Paper (SNIP) 2016: 0.098

Online
ISSN
1558-9544
See all formats and pricing
More options …

Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection

Seth A. Seabury
  • Corresponding author
  • University of Southern California – Department of Emergency Medicine and Leonard D. Schaeffer Center for Health Policy and Economics, 635 Downey Way Verna & Peter Dauterive Hall (VPD), 2nd Floor Los Angeles CA 90089-3333, USA
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Dana P. Goldman
  • University of Southern California – Leonard D. Schaeffer Center for Health Policy and Economics, Los Angeles, CA, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Charu N. Gupta
  • The Wharton School of the University of Pennsylvania – Health Care Management Department, PA, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Zeba M. Khan / Amitabh Chandra / Tomas J. Philipson
  • University of Chicago – Irving B. Harris Graduate School of Policy Studies, Chicago, IL, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Darius N. Lakdawalla
  • University of Southern California – Leonard D. Schaeffer Center for Health Policy and Economics, Los Angeles, CA, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2015-11-18 | DOI: https://doi.org/10.1515/fhep-2015-0028

Abstract

Introduction: There have been significant improvements in both treatment and screening efforts for many types of cancer over the past decade. However, the effect of these advancements on the survival of cancer patients is unknown, and many question the value of both new treatments and screening efforts.

Methods: This study uses a retrospective analysis of SEER Registry data to quantify reductions in mortality rates for cancer patients diagnosed between 1997 and 2007. Using variation in trends in mortality rates by stage of diagnosis across cancer types, we use logistic regression to decompose separate survival gains into those attributable to advances in treatment versus advances in detection. We estimate the gains in survival due to gains in both treatment and detection overall and separately for 15 of the most common cancer types.

Results: We estimate that 3-year cancer-related mortality of cancer patients fell 16.7% from 1997 to 2007. Overall, advances in treatment reduced mortality rates by approximately 12.2% while advances in early detection reduced mortality rates by 4.5%. The relative importance of treatment and detection varied across cancer types. Improvements in detection were most important for thyroid, prostate and kidney cancer. Improvements in treatment were most important for non-Hodgkins lymphoma, lung cancer and myeloma.

Conclusion: Both improved treatment options and better early detection have led to significant survival gains for cancer patients diagnosed from 1997 to 2007, generating considerable social value over this time period.

This article offers supplementary material which is provided at the end of the article.

Keywords: cancer; cancer screening; cancer treatment; medical innovation

References

  • American Cancer Society (2013) Cancer Facts & Figures 2013. Atlanta: American Cancer Society.Google Scholar

  • Bailar 3rd, J. and E. M. Smith (1986) “Progress Against Cancer?” New England Journal of Medicine, 314(19):1226–1232.Web of ScienceCrossrefGoogle Scholar

  • Bleyer, A. and H. G. Welch (2012) “Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence,” New England Journal of Medicine, 367(21):1998–2005.CrossrefWeb of ScienceGoogle Scholar

  • Chu, K. C., C. R. Smart and R. E. Tarone (1988) “Analysis of Breast Cancer Mortality and Stage Distribution by Age for the Health Insurance Plan Clinical Trial,” Journal of the National Cancer Institute, 80(14):1125–1132.PubMedCrossrefGoogle Scholar

  • Citarda, F., G. Tomaselli, R. Capocaccia, S. Barcherini, M. Crespi and I. M. S. Group (2001) “Efficacy in Standard Clinical Practice of Colonoscopic Polypectomy in Reducing Colorectal Cancer Incidence,” Gut, 48(6):812–815.PubMedCrossrefGoogle Scholar

  • Cohen, M. M. and J. M. Diamond (1986) “Medical Research: Are We Losing the War On Cancer?” Nature, 323(6088):488–489.PubMedCrossrefGoogle Scholar

  • Connor, R. J., K. C. Chu and C. R. Smart (1989) “Stage-Shift Cancer Screening Model,” Journal of Clinical Epidemiology, 42(11):1083–1095.CrossrefPubMedGoogle Scholar

  • Cutler, D. M. (2008) “Are We Finally Winning The War on Cancer?” The Journal of Economic Perspectives, 22(4):3–26.CrossrefGoogle Scholar

  • Epstein, S. S. (1990) “Losing the War Against Cancer: Who’s to Blame and What To Do About It,” International Journal of Health Services, 20(1):53–71.CrossrefGoogle Scholar

  • German, R. R., A. K. Fink, M. Heron, S. L. Stewart, C. J. Johnson, J. L. Finch and D. Yin (2011) “The Accuracy of Cancer Mortality Statistics Based on Death Certificates in the United States,” Cancer Epidemiology, 35(2):126–131.CrossrefWeb of SciencePubMedGoogle Scholar

  • Goldman, D. P., C. Gupta, E. Vasudeva, K. Trakas, R. Riley, D. Lakdawalla, D. Agus, N. Sood, A. B. Jena and T. J. Philipson (2013) “The Value of Diagnostic Testing in Personalized Medicine,” Forum for Health Economics and Policy, 16:S87–S99.Google Scholar

  • Howard, D. H., P. B. Bach, E. R. Berndt and R. M. Conti (2015) “Pricing in the Market for Anticancer Drugs,” Journal of Economic Perspectives, 29(1):139–162.Web of ScienceCrossrefGoogle Scholar

  • Lakdawalla, D. N., E. C. Sun, A. B. Jena, C. M. Reyes, D. P. Goldman and T. J. Philipson (2010) “An Economic Evaluation of the War on Cancer,” Journal of Health Economics, 29(3):333–346.Web of SciencePubMedCrossrefGoogle Scholar

  • Leaf, C. (2004) “Why We’re Losing The War on Cancer (and How to Win It),” Fortune (European Edition), 149(5):42–55.Google Scholar

  • Lightwood, J. M. and S. A. Glantz (1997) “Short-term Economic and Health Benefits of Smoking Cessation Myocardial Infarction and Stroke,” Circulation, 96(4):1089–1096.CrossrefPubMedGoogle Scholar

  • Mellman, I., G. Coukos and G. Dranoff (2011) “Cancer Immunotherapy Comes of Age,” Nature, 480(7378):480–489.CrossrefWeb of SciencePubMedGoogle Scholar

  • National Cancer Institute. Overview of the SEER Program. Retrieved May 2, 2014, from http://seer.cancer.gov/about/overview.html.

  • Pharmaceutical Research and Manufacturers of America (2013) 2013 Biopharmaceutical Research Industry Profile. Washington, DC: PhRMA.Google Scholar

  • Philipson, T., M. Eber, D. N. Lakdawalla, M. Corral, R. Conti and D. P. Goldman (2012) “An Analysis of Whether Higher Health Care Spending in the United States versus Europe is ‘worth it’ in the Case of Cancer,” Health Affairs (Millwood), 31(4):667–675.CrossrefGoogle Scholar

  • Seabury, S. A., D. P. Goldman, J. R. Maclean, J. R. Penrod and D. N. Lakdawalla (2012) “Patients Value Metastatic Cancer Therapy More Highly Than Is Typically Shown Through Traditional Estimates,” Health Affairs, 31(4):691–699.CrossrefWeb of ScienceGoogle Scholar

  • Shapiro, S., J. D. Goldberg and G. B. Hutchison (1974). “Lead Time in Breast Cancer Detection and Implications for Periodicity of Screening,” American Journal of Epidemiology, 100(5):357–366.PubMedCrossrefGoogle Scholar

  • Sharma, P., K. Wagner, J. D. Wolchok and J. P. Allison (2011) “Novel Cancer Immunotherapy Agents with Survival Benefit: Recent Successes and Next Steps,” Nature Reviews Cancer, 11(11):805–812.PubMedWeb of ScienceCrossrefGoogle Scholar

  • Soneji, S. and J. Yang (2015) “New Analysis Reexamines The Value Of Cancer Care In The United States Compared To Western Europe,” Health Affairs 34(3):390–397.CrossrefWeb of ScienceGoogle Scholar

  • Sporn, M. B. (1996) “The War On Cancer,” The Lancet, 347(9012):1377–1381.CrossrefGoogle Scholar

  • Sun, E., A. B. Jena, D. Lakdawalla, C. Reyes, T. J. Philipson and D. P. Goldman (2010) “The Contributions of Improved Therapy and Early Detection to Cancer Survival Gains, 1988-2000,” Forum for Health Economics and Policy, 13(2): DOI: 10.2202/1558-9544.1195.Google Scholar

  • Taylor Jr., D. H., V. Hasselblad, S. J. Henley, M. J. Thun and F. A. Sloan (2002). “Benefits of Smoking Cessation for Longevity,” American Journal of Public Health, 92(6):990–996.PubMedCrossrefGoogle Scholar

  • US Department of Health and Human Services. (2013) Percentage of Adults Who Receive Colorectal Cancer Screening as Appropriate. Retrieved April 22, 2014, from https://healthmeasures.aspe.hhs.gov/measure/25.

  • Vanneman, M. and G. Dranoff (2012) “Combining Immunotherapy and Targeted Therapies in Cancer Treatment,” Nature Reviews Cancer, 12(4):237–251.Web of SciencePubMedCrossrefGoogle Scholar

  • Wickens, M. R. (1972) “A Note On The Use of Proxy Variables,” Econometrica, 759–761.Google Scholar

  • Winawer, S. J., A. G. Zauber, M. N. Ho, M. J. O’Brien, L. S. Gottlieb, S. S. Sternberg, J. D. Waye, M. Schapiro, J. H. Bond and J. F. Panish (1993) “Prevention of Colorectal Cancer by Colonoscopic Polypectomy,” New England Journal of Medicine, 329(27):1977–1981.CrossrefGoogle Scholar

About the article

Corresponding author: Seth A. Seabury, University of Southern California – Department of Emergency Medicine and Leonard D. Schaeffer Center for Health Policy and Economics, 635 Downey Way Verna & Peter Dauterive Hall (VPD), 2nd Floor Los Angeles CA 90089-3333, USA, Phone: +(310) 623-2025, e-mail:


Published Online: 2015-11-18

Published in Print: 2016-06-01


Conflict of interest: Support was provided by Celgene Corporation under contract with Precision Health Economics, a health care consultancy. Authors hold the following positions at Precision Health Economics: partner (DPG, TJP, DNL); consultant (SAS); and chief scientific officer (AC). CNG was previously an employee of Precision Health Economics.

Research funding: Support was provided by Celgene Corporation.

Author statement: SAS had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Support was provided by Celgene Corporation under contract with Precision Health Economics, a health care consultancy. Authors hold the following positions at Precision Health Economics: partner (DPG, TJP, DNL); consultant (SAS); and chief scientific officer (AC). CNG was previously an employee of Precision Health Economics. Precision Health Economics maintained all rights to publication subject to a time-limited period for review and comment by Celgene. In addition, ZMK of Celgene Corporation was fully involved with all aspects of this research, including the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.


Citation Information: Forum for Health Economics and Policy, ISSN (Online) 1558-9544, ISSN (Print) 2194-6191, DOI: https://doi.org/10.1515/fhep-2015-0028.

Export Citation

©2016 by De Gruyter. Copyright Clearance Center

Supplementary Article Materials

Comments (0)

Please log in or register to comment.
Log in